Dalton Case is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati. His practice focuses on patent prosecution, serving clients in the chemical, biotechnology, and software industries.
Dalton served as an extern for Judge Bernard Skomal during law school, where he was introduced to patent litigation and discovery. He was also a patent intern at Patterson + Sheridan, LLP during law school, where he assisted with serving clients in the chemical engineering and software industry.
Dalton gained extensive experience in chemical engineering through his undergraduate research at UCLA, where he assisted in designing an ammonia plant in China. Before law school, he also worked at a San Diego winery, where he tested wine in the lab and helped determine flow processes.
Dalton Case is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati. His practice focuses on patent prosecution, serving clients in the chemical, biotechnology, and software industries.
Dalton served as an extern for Judge Bernard Skomal during law school, where he was introduced to patent litigation and discovery. He was also a patent intern at Patterson + Sheridan, LLP during law school, where he assisted with serving clients in the chemical engineering and software industry.
Dalton gained extensive experience in chemical engineering through his undergraduate research at UCLA, where he assisted in designing an ammonia plant in China. Before law school, he also worked at a San Diego winery, where he tested wine in the lab and helped determine flow processes.
- J.D., University of San Diego School of Law, 2020
- B.S. Chemical Engineering, University of California, Los Angeles, 2016
- State Bar of California
- U.S. Patent and Trademark Office
- J.D., University of San Diego School of Law, 2020
- B.S. Chemical Engineering, University of California, Los Angeles, 2016
- State Bar of California
- U.S. Patent and Trademark Office
The proceeds from the financing will be used to advance the clinical development of two drugs: SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin. They are expected to fund the company through end of its Phase 2 meetings with the U.S. Food and Drug Administration (FDA), which are expected in the second half of 2024 for both programs.
Wilson Sonsini has represented DermBiont on IP matters since the company’s inception, and the patent team that advised on the Series B included Matt Bresnahan, Alicia Umpierre, Dalton Case, and Tiara Wong. The Wilson Sonsini corporate team that advised on the transaction included Jason Skolnik, Dani Glazer Signaigo, and Leila Purqurian.
For more information, please see DermBiont’s news release.
- Privacy Policy
- Terms of Use
- Accessibility